Celgene International Sárl (CELG) Release: Premiere Cooperative Group in Adult Lymphoma Research (GELA) Chooses REVLIMID® for Study in Second Most Common Lymphoma Subtype
12/14/2011 6:28:34 AM
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl (Nasdaq: CELG) and the Groupe d’Etude des Lymphomes de l’Adulte (GELA) today announced the organizations have initiated an international, Phase III, open-label, randomized study to evaluate the therapeutic potential of a novel chemotherapy-free approach for the treatment of follicular lymphoma (FL). The combination of REVLIMID (lenalidomide) and rituximab, also referred to as the R-squared (or R2) regimen pioneered by Nathan Fowler, MD and colleagues at the MD Anderson Cancer Center, Houston TX, will be investigated in a study of up to 1,000 patients with newly diagnosed FL. GELA is considered a leading cooperative group for studying the treatment of adult lymphoma patients, and its work has helped establish the standard of care in the treatment of FL as well as other lymphomas.
comments powered by